IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY

Provided are the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen. Se pro...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Lei LIU, Qitao XIAO, Qiangang ZHENG, Gregory MOTZ, Konstantinos John MAVRAKIAS, Jinbiao LIU, Guoliang XUN
Format:	Patent
Sprache:	eng ; spa
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HETEROCYCLIC COMPOUNDS METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Provided are the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen. Se proporciona el uso de inhibidores de LSD1 en relación con el uso y la elaboración de células inmunoefectoras (por ejemplo, células T, células NK). por ejemplo, que se diseñan para expresar un receptor de antígeno quimérico (CAR), con el fin de tratar a un sujeto que tenga una enfermedad, por ejemplo, una enfermedad asociada con la expresión de un antígeno de tumores.